GRFS - Grifols, S.A.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.66
-0.19 (-1.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close18.85
Open18.89
Bid18.65 x 1300
Ask68.07 x 900
Day's Range18.62 - 19.03
52 Week Range17.42 - 24.97
Volume1,225,772
Avg. Volume853,827
Market Cap16.09B
Beta (3Y Monthly)0.97
PE Ratio (TTM)31.13
EPS (TTM)0.60
Earnings DateN/A
Forward Dividend & Yield0.46 (2.27%)
Ex-Dividend Date2018-11-30
1y Target Est21.25
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    Grifols US donor centers exceed 250,000 pounds of food collected

    - About 20% of children in the U.S. are frequently hungry while nearly 50 million Americans do not get enough to eat. RALEIGH, N.C., April 18, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its U.S. network of over 220 donor centers collaborated with local food banks and pantries to collect more than 250,000 pounds of groceries to help address food insecurity in local communities. According to Feeding America, a leading national hunger non-profit, the 253,000 pounds of food collected translates into 211,000i meals to help support the over 50,000 familiesii that cannot put sufficient food on the table.

  • Grifols donations of blood clotting factor helping people with hemophilia globally
    PR Newswire5 days ago

    Grifols donations of blood clotting factor helping people with hemophilia globally

    - The company has donated more than 100 million international units (IUs) of blood clotting factor medicines globally during multi-year commitment to the WFH in developing regions. - Grifols creates Grifols Humanitarian Awards in Hemophilia to strengthen the global fight against the disease. BARCELONA, Spain, April 15, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with hemophilia in developing regions has surpassed 100 million international units (IUs) in donated blood clotting factor, a protein in blood that controls bleeding.

  • PR Newswire15 days ago

    Grifols 2018 Annual Report on Form 20-F Filed With the SEC on April 5, 2019

    BARCELONA, Spain , April 5, 2019 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2018 Annual Report on Form 20-F with the United ...

  • Grifols, S.A. (BME:GRF): What We Can Expect From This Growth Stock
    Simply Wall St.18 days ago

    Grifols, S.A. (BME:GRF): What We Can Expect From This Growth Stock

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Looking at Grifols, S.A.'s (BME:GRF) earnings update in December 2018, the cons...

  • Should You Buy Grifols SA (GRFS)?
    Insider Monkey20 days ago

    Should You Buy Grifols SA (GRFS)?

    "October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]

  • PR Newswire28 days ago

    Grifols Announces the Opening of its new Plasma Donor Center in Russellville, AR

    Investing $1.8 million into local community; set to employ over 40 people from the local area RUSSELLVILLE, Ark. , March 23, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest ...

  • Reuterslast month

    Spain's Grifols, China's Shanghai RAAS form strategic alliance

    Spanish blood products company Grifols said on Thursday it has signed a strategic alliance with Shanghai RAAS as it looks to increase its sales of plasma-derived products in China. Under the agreement, the Catalan company will take a 26.2 percent stake in Shanghai RAAS in exchange for a stake of 45 percent (with 40 percent voting rights) in its U.S. division Grifols Diagnostic Solutions (GDS). Grifols said that no external financing was required to fund the transaction which is expected to close in the second half of 2019 pending regulatory approval.

  • Rigel Pharmaceuticals (RIGL) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Rigel Pharmaceuticals (RIGL) Q4 2018 Earnings Conference Call Transcript

    RIGL earnings call for the period ending December 31, 2018.

  • Grifols PharmacyKeeper Receives KLAS Category Leader Award for Third Consecutive Year
    PR Newswire2 months ago

    Grifols PharmacyKeeper Receives KLAS Category Leader Award for Third Consecutive Year

    This marks the third consecutive year the PharmacyKeeper Verification software has been recognized as the leader in the IV Workflow Management category by KLAS Research, a healthcare IT data and insight-gathering company that collects and publishes impartial research on the software and services used by healthcare providers and payers worldwide. The PharmacyKeeper suite of software applications was developed by MedKeeper, which was acquired by Grifols in January, 2018.

  • 'Young blood' Alzheimer's treatments slapped with warning by FDA commissioner
    American City Business Journals2 months ago

    'Young blood' Alzheimer's treatments slapped with warning by FDA commissioner

    After the FDA warned about "young blood" purporting to treat a range of diseases, including Alzheimer's and post-traumatic stress disorder, a company with a clinical operation in San Francisco has ceased its treatments.

  • East Bay biotech with late-stage drug files for bankruptcy
    American City Business Journals2 months ago

    East Bay biotech with late-stage drug files for bankruptcy

    Over 28 years, the company spent a half-billion dollars on developing inhaled lung-disease drugs that fell short of FDA approval.

  • Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System
    PR Newswire2 months ago

    Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System

    BARCELONA, Spain, Feb. 7, 2019 /PRNewswire/ -- Grifols, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that the U.S. Food and Drug Administration (FDA) approved the Procleix Babesia assay, a qualitative assay for the detection of the ribosomal RNA from 4  Babesia species (B. microti, B. duncani, B. divergens, B. venatorum) in individual samples or up to 16 pooled lysed specimens from human donors, including donors of whole blood and blood components for transfusion.

  • What To Know Before Buying Grifols, S.A. (BME:GRF) For Its Dividend
    Simply Wall St.2 months ago

    What To Know Before Buying Grifols, S.A. (BME:GRF) For Its Dividend

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Dividends play an important role in compounding Read More...

  • Benzinga3 months ago

    Rigel Rises On European Marketing Agreement For Autoimmune Drug

    Small-cap biotech Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL )'s shares were advancing Wednesday after it announced an agreement to commercialize fostamatinib, its autoimmune disorder drug. What Happened ...

  • MarketWatch3 months ago

    Rigel Pharmaceuticals stock up 9% after announcing licensing agreement with Grifols

    Shares of Rigel Pharmaceuticals Inc. shot up 9% in premarket trade Wednesday after the company announced it had entered a license and supply agreement with Spain-based Grifols, S.A. to commercialize fostamatinib disodium hexahydrate, its treatment for thrombocytopenia in adult patients. It is commercially available in the U.S. under the brand name Tavalisse. Under the terms of the agreement, Rigel will receive a $30 million upfront cash payment, with a potential $297.5 million in payments upon reaching certain regulatory and commercial milestones. That figure includes a potential $20 million payment upon the European Medicines Agency approving fostamatinib for the treatment of chronic idiopathic thrombocytopenic purpura (ITP). Rigel will also receive royalty payments based on tiered net sales, which the company said could reach 30% of net sales. In return, Grifols will receive exclusive rights to fostamatinib in Europe and Turkey. However, if fostamatinib has not been approved by the EMA for the treatment of ITP by 2021, Grifols will have the option to terminate the entire agreement, the companies said, and Rigel will have to pay Grifols $25 million to regain all rights to fostamatinib in Europe and Turkey. Rigel shares have fallen 12% in the year to date through Tuesday, while the iShares Nasdaq Biotechnology ETF has gained 12.7%. The S&P 500 has gained 5%.

  • Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
    PR Newswire3 months ago

    Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe

    - Grifols gains exclusive rights to fostamatinib in all potential indications in Europe and Turkey - Rigel to receive an upfront payment of $30 million , with the potential for $297.5 million in total ...

  • Grifols receives FDA approval of Erytra Eflexis®, the latest advancement in scalable blood typing solutions
    PR Newswire3 months ago

    Grifols receives FDA approval of Erytra Eflexis®, the latest advancement in scalable blood typing solutions

    - Erytra Eflexis is a fully automated, benchtop analyzer that performs pretransfusion compatibility testing - This system incorporates two laboratory configurations in a single instrument, providing laboratory ...

  • A Note On Grifols, S.A.’s (BME:GRF) ROE and Debt To Equity
    Simply Wall St.3 months ago

    A Note On Grifols, S.A.’s (BME:GRF) ROE and Debt To Equity

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...

  • A Look At The Fair Value Of Grifols SA (BME:GRF)
    Simply Wall St.4 months ago

    A Look At The Fair Value Of Grifols SA (BME:GRF)

    I am going to run you through how I calculated the intrinsic value of Grifols SA (BME:GRF) by taking the foreast future cash flows of the company and discounting them Read More...

  • Reuters5 months ago

    Shanghai RAAS in tie-up talks with U.S. blood products arm of Spain's Grifols

    China's Shanghai RAAS Blood Products Co Ltd is in talks to combine with a U.S. subsidiary of Spanish blood products company Grifols, the two companies said. Grifols said the talks could lead to it exchanging Grifols Diagnostic Solutions Inc, which it said was valued at around $5 billion, for newly-issued Shanghai RAAS shares. Grifols would have strategic direction of the business.

  • Reuters5 months ago

    BRIEF-Shanghai RAAS Blood Products Plans To Acquire Tiancheng (Germany), Spain's Grifols Diagnostic Solutions

    Nov 22 (Reuters) - Shanghai RAAS Blood Products Co Ltd : * SAYS IT PLANS TO BUY TIANCHENG (GERMANY), WHICH OWNS ABOUT 90 PERCENT OF BIOTEST AG, FOR 589 MILLION EUROS (NOT TO BUY GERMANY'S BIOTEST FOR 589 ...

  • Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol
    PR Newswire6 months ago

    Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol

    - AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plasma science has demonstrated, with statistical significance, the ability to slow down the progression of the disease in moderate AD patients. BARCELONA, Spain, Oct. 27, 2018 /PRNewswire/ -- Presenting the study results, Antonio Páez, M.D., Grifols Medical Director and Head of the AMBAR Clinical Program confirmed that the analysis of AMBAR data in moderate patients has shown positive, highly relevant results in a cohort of patients suffering from moderate Alzheimer's disease.

  • FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing
    PR Newswire6 months ago

    FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing

    Test Offers Shortest Time to Reportable Results For US Hospitals, Reference Labs and Blood Centers - Efficient system analyzes 37 antigens of 10 blood group systems - Helps minimize allo-immunization risk ...

  • Grifols (GRFS) Surges: Stock Moves 5.4% Higher
    Zacks6 months ago

    Grifols (GRFS) Surges: Stock Moves 5.4% Higher

    Grifols (GRFS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.